Characterization of Hepatitis C Virus Resistance from a Multiple-Dose Clinical Trial of the Novel NS5A Inhibitor GS-5885

GS-5885 is a novel hepatitis C virus (HCV) NS5A inhibitor. In a 3-day monotherapy study in treatment-naive genotype 1a (GT1a) and GT1b HCV-infected subjects, median viral load reductions ranged from 2.3 to 3.3 log(10) HCV RNA IU/ml across dosing cohorts (1, 3, 10, 30, or 90 mg once daily). Here, we...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Wong, Kelly A., Worth, Angela, Martin, Ross, Svarovskaia, Evguenia, Brainard, Diana M., Lawitz, Eric, Miller, Michael D., Mo, Hongmei
Format: Artigo
Jezik:Inglês
Izdano: American Society for Microbiology 2013
Teme:
Antiviral Agents
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3837913/
https://ncbi.nlm.nih.gov/pubmed/23877691
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02193-12
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items